Phathom Pharmaceuticals Inc
(NAS:PHAT)
$
8.97
+0.095 (+1.07%)
Market Cap: 725.68 Mil
Enterprise Value: 710.32 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 25/100 Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023 / 12:45PM GMT
Release Date Price:
$9.94
(-4.61%)
Joey Stringer
Needham & Company - Analyst
Good morning, everyone. Thank you for joining the 22nd Annual Needham Healthcare Conference. My name is Joey Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, that's Phathom Pharmaceuticals. Joining us today from the company is President and CEO, Terrie Curran; CFO, Molly Henderson; Chief Operating Officer, Azmi Nabulsi; Chief Commercial Officer, Martin Gilligan; and also, Chief Development Officer, Tom Harris. I think I got everyone.
(Conference Instructions) So, with that, that was with the Phanthom team. Thanks so much for joining us today.
Terrie Curran
Phathom Pharmaceuticals, Inc. - President & CEO
Thanks, Joey, and thanks for the invitation to be here. It's a real pleasure.
Joey Stringer
Needham & Company - Analyst
Of course.
Terrie Curran
Phathom Pharmaceuticals, Inc. - President & CEO
So, I'll pick it up, and I
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot